您是第 11218132 位 欢迎访问 中乔新舟官网 ! 全国免费电话:400-038-9959 我的购物车(0) 注 册 / 登 录
扫码关注公众号
您当前的位置:首页 > 产品中心

HPAF-II人胰腺癌细胞 (STR鉴定)

英文名:HPAF-II
货号:ZQ0696
价格:¥1500.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

HPAF-II人胰腺癌细胞 (STR鉴定)

¥1500.00
+

HPAF-II人胰腺癌细胞专用培养基

¥350.00 ¥500.00

配套完培,省时省力,单买细胞无优惠

=

细胞套餐惊爆价

¥1850 ¥2300.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

HPAF-II人胰腺癌细胞

货号

ZQ0696

产品介绍

HPAF-II是一种人胰腺癌细胞系,来源于一名44岁高加索男性的腹膜腹水,该男性患有原发性胰腺癌并转移至肝脏、膈肌和淋巴结。。该细胞系由于其与研究胰腺癌(一种高度侵袭性和致命的恶性肿瘤)的相关性而常用于癌症研究。 HPAF-II 细胞表现出上皮形态,并以其在异种移植到免疫功能低下的小鼠体内时形成肿瘤的能力而闻名,这使它成为肿瘤生长、转移和对治疗干预反应的体内研究的有价值的模型。研究人员经常使用 HPAF-II 细胞来研究胰腺癌进展的分子机制,包括遗传和表观遗传改变、信号转导途径以及与肿瘤微环境的相互作用。
HPAF-II 细胞的特征是在胰腺腺癌中经常观察到的特定基因突变和改变。其中包括 KRAS 基因的突变(该基因在细胞信号传导和增殖中发挥着关键作用)以及肿瘤抑制基因(如 TP53 和 CDKN2A)的改变。该细胞系还表现出高水平的粘蛋白产生,这一特征有助于胰腺肿瘤的侵袭性。利用 HPAF-II 细胞的研究为胰腺癌的生物学提供了重要的见解,并促进了旨在针对与该疾病相关的关键分子途径的潜在治疗策略的开发。

注意事项:大部分肿瘤细胞的胞体上/内有黑色颗粒,培养液中含有少量黑色颗粒是正常的。细胞呈现块状生长形态。

种属

性别/年龄

男/44岁

组织

胰腺

疾病

腺癌

细胞类型

肿瘤细胞 

形态学

上皮的

生长方式

贴壁

倍增时间

 大约26~70小时

培养基和添加剂

MEM(中乔新舟 货号:ZQ-300)+10%进口胎牛血清(中乔新舟  货号:ZQ500-A)+1%P/S(中乔新舟  货号:CSP006)+1% Sodium Pyruvate 100 mM Solution(中乔新舟  货号:CSP003)+1%L-alanyl-L-glutamine(中乔新舟   货号:CSP004

推荐完全培养基货号

ZM0696

生物安全等级

BSL-1

STR位点信息

Amelogenin: X

CSF1PO: 10,11

D13S317: 12

D16S539: 11,13

D5S818: 11,13

D7S820: 10,13

F13A01: 5,17

F13B: 8,10

FESFPS: 11,12

LPL: 10

THO1: 9

TPO

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

 ***

基因表达

 ***

保藏机构

ATCC; CRL-1997 

供应限制

仅供科研使用

货号

ZQ0696

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


PubMed=2734279; DOI=10.1097/00006676-198906000-00013
Kim Y.W., Kern H.F., Mullins T.D., Koriwchak M.J., Metzgar R.S.
Characterization of clones of a human pancreatic adenocarcinoma cell line representing different stages of differentiation.
Pancreas 4:353-362(1989)


PubMed=1764370; DOI=10.1038/bjc.1991.467
Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N., Lane D.P., Lemoine N.R.
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.
Br. J. Cancer 64:1076-1082(1991)


PubMed=11787853; DOI=10.1007/s004280100474
Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr J.-M., Scarpa A.
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
Virchows Arch. 439:798-802(2001)


PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)


PubMed=12692724; DOI=10.1007/s00428-003-0784-4
Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.
Virchows Arch. 442:444-452(2003)


PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159
Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L., Veltman J.A., van Kessel A.G., Hoglund M.
Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.
Cancer Res. 64:3052-3059(2004)


PubMed=15367885; DOI=10.1097/00006676-200410000-00004
Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M., Hirohashi S.
Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
Pancreas 29:193-203(2004)


PubMed=15367897; DOI=10.1097/00006676-200410000-00016
Rajasekaran S.A., Gopal J., Espineda C., Ryazantsev S., Schneeberger E.E., Rajasekaran A.K.
HPAF-II, a cell culture model to study pancreatic epithelial cell structure and function.
Pancreas 29:E77-E83(2004)


PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x
Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.
Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
Cancer Sci. 99:986-994(2008)


DOI=10.4172/jpb.1000057
Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T.
The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis.
J. Proteomics Bioinformatics 2:1-18(2009)


PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)


PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963
Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J.
Phenotype and genotype of pancreatic cancer cell lines.
Pancreas 39:425-435(2010)


PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)


PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
      上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经十多年发展,...
联系我们 / Contact
电 话:021-56760357;021-56760351
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved. 网站地图

沪公网安备 31011002001038号

技术支持:攸攸网络 沪ICP备14008091号